Skip to main
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute Inc continues to demonstrate promising advancements in its clinical pipeline, particularly in the management of congenital hyperinsulinism, as evidenced by significant reductions in hypoglycemia events in trials. A particularly noteworthy outcome from the Phase 2b RIZE study indicates a remarkable 70-90% reduction in weekly hypoglycemia events with the company's drug candidates, supporting the efficacy of their therapies. Additionally, the favorable safety profile of ersodetug, along with the potential for positive regulatory outcomes, strengthens the positive outlook for the company's future revenue and value creation.

Bears say

Rezolute Inc faces significant challenges following the failure of its lead candidate, Ersodetug, which did not demonstrate a statistically significant benefit compared to placebo, leaving both the company and investors disappointed. Additionally, the sunRIZE trial missed key secondary endpoints, highlighting the difficulties in measuring treatment efficacy in an outpatient setting where patient behavior may affect results. The company operates in a high-risk environment characterized by clinical trial uncertainties, regulatory hurdles, and a competitive market landscape, all of which negatively impact its revenue potential and overall stock outlook.

Rezolute (RZLT) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Buy based on their latest research and market trends.

According to 6 analysts, Rezolute (RZLT) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.